Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases.

  title={Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases.},
  author={Richard C Grondin and Zhi-Ming Zhang and Y. D. Ai and Don M. Gash and Greg A. Gerhardt},
  journal={Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques},
Parkinson's disease is characterized by a progressive degeneration of the substantia nigra pars compacta dopamine neurons that innervate the striatum. Unlike current treatments for PD, GDNF administration could potentially slow or halt the continued degeneration of nigral dopaminergic neurons. GDNF does not cross the blood-brain barrier and needs to be administered directly into the brain. Due to the progressive nature of PD, sustained delivery of trophic factors may be necessary for optimal… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 12 extracted citations

Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP

Cell and Tissue Research • 2004
View 4 Excerpts
Highly Influenced

Non-destructive methods of characterization of risperidone solid lipid nanoparticles.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…